Werfen Announces US FDA 510(k) Clearance and CE Mark for Aptiva® Antiphospholipid Syndrome IgA Reagent

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Werfen

More Like This

PR Newswire associated0

Werfen Receives CE Mark for Aptiva® Antiphospholipid Syndrome Reagents

PR Newswire associated0

MosaiQ AiPlex® Vasculitis assay now available for clinical use in the European Union and other CE mark accepting countries

PR Newswire associated0

AliveDx announces U.S. Food and Drug Administration (FDA) 510(k) submission for its MosaiQ AiPlex® Vasculitis (VAS) assay.

PR Newswire associated0

Roche receives CE mark for first IVD immunoassay blood test to identify carriers of ApoE4, a genetic variant present in up to 60% of patients diagnosed with Alzheimer's disease

Fujirebio Receives Marketing Clearance for Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer’s Disease

Fujirebio Submits FDA Regulatory Filing for Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer’s Disease

AliveDx Expands Autoimmune Menu with IVDR-CE Marked MosaiQ AiPlex® CTDplus Multiplex Assay to Aid in Diagnosing Systemic Autoimmune Rheumatic Diseases and Streamline Laboratory Workflow

Fujirebio Expands Access to Blood-based Neurology Testing in Brazil with ANVISA Market Authorization for Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma